Home - Prosigna TM - How it works


How the Prosigna test works






Prosigna™ is a genetic test (CE / IVD - FDA) that relies on the analysis system NanoString nCounter® DX to evaluate the expression profile of a group of 50 genes implicated in the progression of breast cancer.


Prosigna™ is the only test that can simultaneously classify genetic breast cancers and assess simultaneously the category of risk of tumor recurrence at 10 years for women undergoing breast cancer surgery.


The risk of relapse is expressed as a numerical score from 0 to 100; in order to define three risk categories (low, intermediate and high). The genetic classification of the tumor allows for more accurate guidance on choosing the best individual treatment for each patient and providing an indication of the prognosis.




 download    Download the brochure



 Anatomic Pathology Unit

 Laboratory of Molecular Diagnostis


 from Monday to Friday, hours 9:00 - 17:00;

 Saturday, hours 9:00 - 14:00





 from Monday to Friday, hours 8:00 - 19:00

 Tel.: (+39) 06.22541.1240





Questo sito utilizza i Cookies per migliorare l’esperienza di navigazione e la qualità dei nostri servizi. Continuando la navigazione dichiari di accettare l’utilizzo dei Cookies presenti sul sito. Per saperne di più.